BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sunakawa Y, Lenz HJ. Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. Curr Treat Options Oncol. 2015;16:17. [PMID: 25813036 DOI: 10.1007/s11864-015-0331-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Marrelli D, Polom K, Pascale V, Vindigni C, Piagnerelli R, De Franco L, Ferrara F, Roviello G, Garosi L, Petrioli R, Roviello F. Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer. Ann Surg Oncol. 2016;23:943-950. [PMID: 26530444 DOI: 10.1245/s10434-015-4931-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
2 Tang L, Tong SJ, Zhan Z, Wang Q, Tian Y, Chen F. Expression of NUAK2 in gastric cancer tissue and its effects on the proliferation of gastric cancer cells. Exp Ther Med 2017;13:676-80. [PMID: 28352350 DOI: 10.3892/etm.2016.3983] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Xu J, Wang Z, Lu W, Jiang H, Lu J, Qiu J, Ye G. EZH2 promotes gastric cancer cells proliferation by repressing p21 expression. Pathol Res Pract 2019;215:152374. [PMID: 30952377 DOI: 10.1016/j.prp.2019.03.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
4 Li Y, Yuan S, Liu J, Wang Y, Zhang Y, Chen X, Si W. CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF. J Cell Physiol 2020;235:2071-9. [PMID: 31347172 DOI: 10.1002/jcp.29107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
5 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
6 Wei F, Wang Y, Zhou Y, Li Y. Long noncoding RNA CYTOR triggers gastric cancer progression by targeting miR-103/RAB10. Acta Biochim Biophys Sin (Shanghai) 2021;53:1044-54. [PMID: 34110382 DOI: 10.1093/abbs/gmab071] [Reference Citation Analysis]
7 Neves Filho EHC, Pires APB, de Sant'Ana RO, Rabenhorst SHB, Hirth CG, da Cunha MDPSS. The association among HER2, MET and FOXP3 expression and tumor regression grading in gastric adenocarcinoma. APMIS 2018;126:389-95. [PMID: 29696715 DOI: 10.1111/apm.12840] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Sun KK, Wang QH, Wu YY. Challenges surrounding postoperative adjuvant chemotherapy for T2N0 gastric cancer. Oncol Lett 2020;20:126. [PMID: 32934695 DOI: 10.3892/ol.2020.11985] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Kang BW, Seo AN, Yoon S, Bae HI, Jeon SW, Kwon OK, Chung HY, Yu W, Kang H, Kim JG. Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer. Ann Oncol. 2016;27:494-501. [PMID: 26673353 DOI: 10.1093/annonc/mdv610] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 10.0] [Reference Citation Analysis]
10 Pretzsch E, Bösch F, Todorova R, Nieß H, Jacob S, Guba M, Kirchner T, Werner J, Klauschen F, Angele MK, Neumann J. Molecular subtyping of gastric cancer according to ACRG using immunohistochemistry – correlation with clinical parameters. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153797] [Reference Citation Analysis]
11 Hissong E, Ramrattan G, Zhang P, Zhou XK, Young G, Klimstra DS, Shia J, Fernandes H, Yantiss RK. Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features. Am J Surg Pathol. 2018;42:453-462. [PMID: 29438172 DOI: 10.1097/pas.0000000000001018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
12 Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, Hong TS, Kwak EL, Lauwers GY. A protein and mRNA expression-based classification of gastric cancer. Mod Pathol. 2016;29:772-784. [PMID: 27032689 DOI: 10.1038/modpathol.2016.55] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 11.8] [Reference Citation Analysis]
13 DIaz Del Arco C, Estrada Muñoz L, Molina Roldán E, Ortega Medina L, García Gómez de Las Heras S, Chávez Á, Fernández Aceñero M. Proposal for a clinicopathological prognostic score for resected gastric cancer patients. Saudi J Gastroenterol 2021;27:44-53. [PMID: 33047677 DOI: 10.4103/sjg.SJG_208_20] [Reference Citation Analysis]
14 Kang HJ, Lee I, Park Y, Ho WJ, Sohn D, Ahn J, Yook J, Kim B. Biomarkers of EBV-positive Gastric Cancers: Loss of PTEN Expression is Associated with Poor Prognosis and Nodal Metastasis. Ann Surg Oncol 2016;23:3684-92. [DOI: 10.1245/s10434-016-5284-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhao W, Ding G, Wen J, Tang Q, Yong H, Zhu H, Zhang S, Qiu Z, Feng Z, Zhu J. Correlation between Trop2 and amphiregulin coexpression and overall survival in gastric cancer. Cancer Med 2017;6:994-1001. [PMID: 28256068 DOI: 10.1002/cam4.1018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
16 Basak D, Jamal Z, Ghosh A, Mondal PK, Dey Talukdar P, Ghosh S, Ghosh Roy B, Ghosh R, Halder A, Chowdhury A, Dhali GK, Chattopadhyay BK, Saha ML, Basu A, Roy S, Mukherjee C, Biswas NK, Chatterji U, Datta S. Reciprocal interplay between asporin and decorin: Implications in gastric cancer prognosis. PLoS One 2021;16:e0255915. [PMID: 34379688 DOI: 10.1371/journal.pone.0255915] [Reference Citation Analysis]
17 Arakawa N, Sugai T, Habano W, Eizuka M, Sugimoto R, Akasaka R, Toya Y, Yamamoto E, Koeda K, Sasaki A, Matsumoto T, Suzuki H. Genome-wide analysis of DNA copy number alterations in early and advanced gastric cancers. Mol Carcinog 2017;56:527-37. [PMID: 27312513 DOI: 10.1002/mc.22514] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
18 Pereira MA, Ramos MFKP, Dias AR, Faraj SF, Ribeiro RRE, de Castria TB, Zilberstein B, Alves VAF, Ribeiro U Jr, de Mello ES. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1. Mol Diagn Ther 2019;23:761-71. [PMID: 31595457 DOI: 10.1007/s40291-019-00424-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
19 Jiang X, Wu M, Xu X, Zhang L, Huang Y, Xu Z, He K, Wang H, Wang H, Teng L. COL12A1, a novel potential prognostic factor and therapeutic target in gastric cancer. Mol Med Rep 2019;20:3103-12. [PMID: 31432110 DOI: 10.3892/mmr.2019.10548] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
20 Cisło M, Filip AA, Arnold Offerhaus GJ, Ciseł B, Rawicz-Pruszyński K, Skierucha M, Polkowski WP. Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology. Oncotarget 2018;9:19427-42. [PMID: 29721214 DOI: 10.18632/oncotarget.24827] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
21 Zhao W, Zhu H, Zhang S, Yong H, Wang W, Zhou Y, Wang B, Wen J, Qiu Z, Ding G, Feng Z, Zhu J. Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget 2016;7:6136-45. [PMID: 26716416 DOI: 10.18632/oncotarget.6733] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
22 Song L, Song M, Camargo MC, Van Duine J, Williams S, Chung Y, Kim KM, Lissowska J, Sivins A, Gao W, Karthikeyan K, Park J, Leja M, Cohen JI, LaBaer J, Qiu J, Rabkin CS. Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma. Gastric Cancer 2021;24:858-67. [PMID: 33661412 DOI: 10.1007/s10120-021-01170-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Lima Á, Sousa H, Medeiros R, Nobre A, Machado M. PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis. Discov Oncol 2022;13:19. [PMID: 35318527 DOI: 10.1007/s12672-022-00479-0] [Reference Citation Analysis]
24 Liu X, Yang Z, Latchoumanin O, Qiao L. Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. Therap Adv Gastroenterol. 2016;9:853-860. [PMID: 27803740 DOI: 10.1177/1756283x16658251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
25 Ahn S, Lee SJ, Kim Y, Kim A, Shin N, Choi KU, Lee CH, Huh GY, Kim KM, Setia N, Lauwers GY, Park DY. High-throughput Protein and mRNA Expression-based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications. Am J Surg Pathol. 2017;41:106-115. [PMID: 27819872 DOI: 10.1097/pas.0000000000000756] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 9.2] [Reference Citation Analysis]
26 Zhang W, Cui N, Ye J, Yang B, Sun Y, Kuang H. Curcumin's prevention of inflammation-driven early gastric cancer and its molecular mechanism. Chinese Herbal Medicines 2022. [DOI: 10.1016/j.chmed.2021.11.003] [Reference Citation Analysis]
27 Wang W, Wang K, Chen Z, Chen L, Guo W, Liao P, Rotroff D, Knepper TC, Liu Z, Zhang W, Mcleod HL, He Y. Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients. Oncotarget 2018;9:12164-73. [PMID: 29552300 DOI: 10.18632/oncotarget.24037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
28 Lee V, Murphy A, Le DT, Diaz LA Jr. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. Oncologist. 2016;21:1200-1211. [PMID: 27412392 DOI: 10.1634/theoncologist.2016-0046] [Cited by in Crossref: 116] [Cited by in F6Publishing: 113] [Article Influence: 19.3] [Reference Citation Analysis]
29 Zhang ZG, Xu L, Zhang PJ, Han L. Evaluation of the value of multiparameter combined analysis of serum markers in the early diagnosis of gastric cancer. World J Gastrointest Oncol 2020; 12(4): 483-491 [PMID: 32368325 DOI: 10.4251/wjgo.v12.i4.483] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Li J, Xu L, Run ZC, Feng W, Liu W, Zhang PJ, Li Z. Multiple cytokine profiling in serum for early detection of gastric cancer. World J Gastroenterol 2018; 24(21): 2269-2278 [PMID: 29881236 DOI: 10.3748/wjg.v24.i21.2269] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
31 Ignatova EO, Kozlov E, Ivanov M, Mileyko V, Menshikova S, Sun H, Fedyanin M, Tryakin A, Stilidi I. Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma. World J Gastrointest Oncol 2022; 14(3): 628-645 [DOI: 10.4251/wjgo.v14.i3.628] [Reference Citation Analysis]
32 Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T, Wang Q, Jiang J. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget 2017;8:64066-82. [PMID: 28969052 DOI: 10.18632/oncotarget.19318] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
33 de Fátima Aquino Moreira-Nunes C, de Souza Almeida Titan Martins CN, Feio D, Lima IK, Lamarão LM, de Souza CRT, Costa IB, da Silva Maués JH, Soares PC, de Assumpção PP, Burbano RMR. PD-L1 Expression Associated with Epstein-Barr Virus Status and Patients' Survival in a Large Cohort of Gastric Cancer Patients in Northern Brazil. Cancers (Basel) 2021;13:3107. [PMID: 34206307 DOI: 10.3390/cancers13133107] [Reference Citation Analysis]
34 Pereira MA, Ramos MFKP, Dias AR, Cardili L, Ribeiro RRE, de Castria TB, Zilberstein B, Nahas SC, Ribeiro U Jr, de Mello ES. RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients. Med Sci (Basel) 2021;10:4. [PMID: 35076580 DOI: 10.3390/medsci10010004] [Reference Citation Analysis]
35 Rodriquenz MG, Roviello G, D'Angelo A, Lavacchi D, Roviello F, Polom K. MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy. J Clin Med 2020;9:E1427. [PMID: 32403403 DOI: 10.3390/jcm9051427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
36 Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, Battaglin F, Soni S, McSkane M, Zhang W, Lenz HJ. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 2018;66:15-22. [PMID: 29631196 DOI: 10.1016/j.ctrv.2018.03.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 12.5] [Reference Citation Analysis]
37 Pereira MA, Ramos MFKP, Faraj SF, Dias AR, Yagi OK, Zilberstein B, Cecconello I, Alves VAF, de Mello ES, Ribeiro U Jr. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. J Surg Oncol 2018;117:829-39. [PMID: 29534305 DOI: 10.1002/jso.25022] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]
38 Re V, Brisotto G, Repetto O, De Zorzi M, Caggiari L, Zanussi S, Alessandrini L, Canzonieri V, Miolo G, Puglisi F, Belluco C, Steffan A, Cannizzaro R. Overview of Epstein-Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options. Int J Mol Sci 2020;21:E9400. [PMID: 33321820 DOI: 10.3390/ijms21249400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]